Blood Test Tracks Breast Cancer Recurrence Through DNA Packaging Patterns

A research team at Kumamoto University has identified a blood-based method for flagging breast cancer recurrence that looks beyond the DNA mutations conventionally tracked in liquid biopsies, focusing instead on how DNA is packaged inside cells.

Published in Cancer Research Communications, the study examined cell-free DNA (cfDNA)—short DNA fragments that circulate in the bloodstream—from 150 breast cancer samples, 105 from primary tumors and 45 from recurrent or metastatic disease.

Instead of focusing only on changes in DNA sequence, the team examined nucleosomes: structures formed when DNA wraps around histone proteins. How nucleosomes are arranged reflects gene regulation and how tightly or loosely a region of DNA is packaged, meaning blood-derived DNA can carry information about what is happening inside cancer cells.

The researchers targeted 26 genomic regions already linked to transcriptional shifts that occur when breast cancer cells become resistant to hormone therapy. Recurrent breast cancer was associated with a higher number of genetic variants and shorter cfDNA fragments compared with primary disease. 

Two regions in particular, RERE and SYNPO2, stood out. A nucleosome-based score built from these two regions separated primary from recurrent breast cancer with an area under the curve of 0.826, a result the researchers describe as strong discriminatory performance. Using machine learning to combine the nucleosome data with other cfDNA characteristics improved recurrence prediction even further.

The results indicate that cfDNA analysis can capture more than mutation status alone—it may also pick up changes in gene regulation and chromatin structure tied to treatment resistance and disease recurrence.

Because the method relies on a blood draw, it could eventually support low-invasive monitoring of patients throughout and after treatment, helping catch recurrence earlier and informing more personalized treatment decisions. 

The team cautions that the work drew on a relatively limited retrospective cohort, and that differences in breast cancer subtypes and patient backgrounds between the primary and recurrent groups still need to be addressed. Larger, prospective studies will be needed to establish how broadly the approach can be applied in clinical practice.